pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

4,158 catalysts · 3,183 8k filing · 577 earnings · 172 phase 2 completion · 138 grant · 133 drug shortage · 89 approval

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-08-10: 0 catalysts2026-08-11: 0 catalysts2026-08-12: 76 catalysts2026-08-13: 19 catalysts2026-08-14: 4 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 1 catalyst2026-08-18: 2 catalysts2026-08-19: 3 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 1 catalyst2026-08-27: 1 catalyst2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 1 catalyst2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 2 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 2 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 1 catalyst2026-10-14: 1 catalyst2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts2026-10-19: 1 catalyst2026-10-20: 2 catalysts2026-10-21: 2 catalysts2026-10-22: 2 catalysts2026-10-23: 1 catalyst2026-10-24: 0 catalysts2026-10-25: 0 catalysts2026-10-26: 1 catalyst2026-10-27: 8 catalysts2026-10-28: 12 catalysts2026-10-29: 21 catalysts2026-10-30: 4 catalysts2026-10-31: 0 catalysts2026-11-01: 0 catalysts2026-11-02: 9 catalysts2026-11-03: 18 catalysts2026-11-04: 22 catalysts2026-11-05: 37 catalysts2026-11-06: 2 catalysts2026-11-07: 0 catalysts2026-11-08: 0 catalysts
view
agendamonth
sort
soonestlatesttypesponsoralpha
from 2026-04-10×clear all
type
  • 8k filing3,183
  • earnings577
  • phase 2 completion172
  • grant138
  • drug shortage133
  • approval89
phase 1 completion
73
  • phase 2 initiation62
  • phase 1 initiation40
  • recall37
  • therapy area
    • Oncology148
    • Infectious Disease46
    • Cardiology37
    • Immunology35
    • Dermatology31
    • Pulmonology22
    • Women's Health19
    • Ophthalmology16
    • Pain15

    Week of Apr 27, 2026

    50
    ›Apr 27, 20268k filing108d agoLIGAND PHARMACEUTICALS INC (LGND, LGNDZ, LGNXZ, LGNYZ, LGNZZ) — 8-K filing

    Items: 1.01, 8.01

    full page →edgar 8k ↗
    ›Apr 27, 20268k filing108d ago$FOLD — AMICUS THERAPEUTICS, INC. (FOLD) — 8-K filing

    Items: 1.02, 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01

    full page →edgar 8k ↗
    ›Apr 27, 20268k filing108d ago$ERAS — Erasca, Inc. (ERAS) — 8-K filing

    Items: 8.01

    full page →edgar 8k ↗
    ›Apr 27, 20268k filing108d agoCDT Equity Inc. (CDT, CDTTW) — 8-K filing

    Items: 5.02

    full page →edgar 8k ↗
    ›Apr 27, 20268k filing108d ago$XNCR — Xencor Inc (XNCR) — 8-K filing

    Items: 5.02, 9.01

    full page →edgar 8k ↗
    ›Apr 27, 20268k filing108d ago$ABT — ABBOTT LABORATORIES (ABT) — 8-K filing

    Items: 5.02, 5.03, 5.07, 9.01

    full page →edgar 8k ↗
    ›Apr 27, 20268k filing108d agoXOMA Royalty Corp (XOMA, XOMAO, XOMAP) — 8-K filing

    Items: 2.01, 8.01, 9.01

    full page →edgar 8k ↗
    ›Apr 27, 20268k filing108d agoProfusa, Inc. (PFSA, NVACW) — 8-K filing

    Items: 1.01, 3.02, 8.01, 9.01

    full page →edgar 8k ↗
    ›Apr 27, 20268k filing108d ago$INM — InMed Pharmaceuticals Inc. (INM) — 8-K filing

    Items: 1.01, 3.03, 8.01, 9.01

    full page →edgar 8k ↗
    ›Apr 27, 20268k filing108d ago$MANE — Veradermics, Inc (MANE) — 8-K filing

    Items: 2.02

    full page →edgar 8k ↗
    ›Apr 27, 20268k filing108d ago$PFE — PFIZER INC (PFE) — 8-K filing

    Items: 5.07

    full page →edgar 8k ↗
    ›Apr 27, 20268k filing108d ago$PAHC — PHIBRO ANIMAL HEALTH CORP (PAHC) — 8-K filing

    Items: 7.01, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 2026constraining patent expiry europe107d agoLupin Ltd — (dolutegravir + lamivudine + tenofovir disoproxil fumarate) (Constraining Patent Expiry (Europe))(dolutegravir + lamivudine + tenofovir disoproxil fumarate)

    Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

    full page →(dolutegravir + lamivudine + tenofovir disoproxil fumarate) →source: globaldata
    ›Apr 28, 2026patent expiry107d agoGSK plc — dolutegravir sodium ODT (Constraining Patent Expiry (Japan))dolutegravir sodium

    Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

    full page →dolutegravir sodium →source: globaldata
    ›Apr 28, 2026patent expiry107d agoGSK plc — (abacavir sulfate + dolutegravir sodium+ lamivudine) ODT (Constraining Patent Expiry (Japan))(abacavir sulfate + dolutegravir sodium + lamivudine)

    Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

    full page →(abacavir sulfate + dolutegravir sodium + lamivudine) →source: globaldata
    ›Apr 28, 2026patent expiry107d agoGSK plc — cabotegravir sodium (Constraining Patent Expiry (US))cabotegravir sodium

    Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

    full page →cabotegravir sodium →source: globaldata
    ›Apr 28, 2026patent expiry107d agoViiV Healthcare UK Ltd — cabotegravir + rilpivirine LA (Constraining Patent Expiry (US))cabotegravir + rilpivirine LA

    Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

    full page →cabotegravir + rilpivirine LA →source: globaldata
    ›Apr 28, 2026patent expiry107d agoViiV Healthcare UK Ltd — cabotegravir LA (Constraining Patent Expiry (US))cabotegravir LA

    Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

    full page →cabotegravir LA →source: globaldata
    ›Apr 28, 2026drug expiry107d agoGSK plc — cabotegravir sodium (Drug Expiry (US))cabotegravir sodium

    Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

    full page →cabotegravir sodium →source: globaldata
    ›Apr 28, 2026drug expiry107d agoViiV Healthcare UK Ltd — cabotegravir LA (Drug Expiry (US))cabotegravir LA

    Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

    full page →cabotegravir LA →source: globaldata
    ›Apr 28, 2026drug expiry107d agoViiV Healthcare UK Ltd — cabotegravir + rilpivirine LA (Drug Expiry (US))cabotegravir + rilpivirine LA

    Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

    full page →cabotegravir + rilpivirine LA →source: globaldata
    ›Apr 28, 2026pdufa107d agoMerck & Co Inc — (doravirine + islatravir hydrate) (PDUFA)(doravirine + islatravir hydrate)

    Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

    full page →(doravirine + islatravir hydrate) →source: globaldata
    ›Apr 28, 2026phase 1 completion107d agoNational Cancer Institute US — undisclosed chemotherapy (Phase I Trial Completion)undisclosed chemotherapy

    Therapy area: Gastrointestinal, Oncology. Indication: Bile Duct Cancer (Cholangiocarcinoma), Hepatocellular Carcinoma, Liver Cancer, Liver Cirrhosis, Metastatic Liver Cancer

    full page →undisclosed chemotherapy →source: globaldata
    ›Apr 28, 2026phase 1 completion107d agoLatigo Biotherapeutics Inc — LTG-001 (Phase I Trial Completion)LTG-001

    Therapy area: Central Nervous System. Indication: Unspecified Pain

    full page →LTG-001 →source: globaldata
    ›Apr 28, 2026phase 1 completion107d agoInternational Bio Service Co Ltd — Bisoprolol fumarate (Phase I Trial Completion)BISOPROLOL FUMARATE

    Therapy area: Cardiovascular. Indication: Hypertension

    full page →BISOPROLOL FUMARATE →source: globaldata
    ›Apr 28, 2026phase 1 completion107d agoGSK plc — bepirovirsen sodium (Phase I Trial Completion)bepirovirsen sodium

    Therapy area: Infectious Disease. Indication: Hepatitis B

    full page →bepirovirsen sodium →source: globaldata
    ›Apr 28, 2026phase 1 completion107d agoTsuno Rice Fine Chemicals Co Ltd — magnesium (Phase I Trial Completion)magnesium

    Therapy area: Undisclosed. Indication: Unspecified

    full page →magnesium →source: globaldata
    ›Apr 28, 2026phase 1 completion107d agoBeijing Cancer Hospital — JCXH-212 (Phase I Trial Completion)JCXH-212

    Therapy area: Oncology. Indication: Non-Small Cell Lung Cancer, Solid Tumor

    full page →JCXH-212 →source: globaldata
    ›Apr 28, 2026phase 1 completion107d agoBio-Innova Co Ltd — clarithromycin (Phase I Trial Completion)clarithromycin

    Therapy area: Central Nervous System, Dermatology, Ear Nose Throat Disorders, Gastrointestinal, Genito Urinary System, Infectious Disease, Mouth and Dental Disorders, Respiratory. Indication: Abscess, Acne Vulgaris, Acute Bacterial Sinusitis, Acute Bronchitis, Acute Pharyngitis, Bacterial Pneumonia, Bacterial Respiratory Tract Infections, Bartonella Infections, Bronchitis, Carbuncle, Cellulitis, Chlamydia trachomatis Pneumonia, Chronic Bronchitis, Community Acquired Pneumonia, Community-Acquired

    full page →clarithromycin →source: globaldata
    ›Apr 28, 2026phase 1 completion107d agoPolfa Tarchomin SA — empagliflozin (Phase I Trial Completion)SYNJARDY

    Therapy area: Cardiovascular, Metabolic Disorders. Indication: Congestive Heart Failure (Heart Failure), Type 2 Diabetes

    full page →SYNJARDY →source: globaldata
    ›Apr 28, 2026phase 1 initiation107d agoShanghai Argo Pharmaceutical Co Ltd — BW-20805 (Phase I Trial Initiation)BW-20805

    Therapy area: Immunology. Indication: Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency)

    full page →BW-20805 →source: globaldata
    ›Apr 28, 2026phase 1 initiation107d agoShenzhen MagicRNA Biotech Co Ltd — HN-2302 (Phase I Trial Initiation)HN-2302

    Therapy area: Immunology. Indication: Autoimmune Disorders, Diffuse Cutaneous Systemic Sclerosis, Systemic Sclerosis (Scleroderma)

    full page →HN-2302 →source: globaldata
    ›Apr 28, 2026phase 1 initiation107d agoBio-Innova Co Ltd — febuxostat (Phase I Trial Initiation)febuxostat

    Therapy area: Metabolic Disorders, Musculoskeletal Disorders. Indication: Gouty Arthritis (Gout), Hyperuricemia

    full page →febuxostat →source: globaldata
    ›Apr 28, 2026phase 1 initiation107d agoVirginia Commonwealth University — fluorouracil (Phase I Trial Initiation)Efudex

    Therapy area: Dermatology. Indication: Burns

    full page →Efudex →source: globaldata
    ›Apr 28, 2026phase 1 initiation107d agoNovo Nordisk AS — cagrilintide hydrochloride (Phase I Trial Initiation)cagrilintide hydrochloride

    Therapy area: Metabolic Disorders. Indication: Obesity, Overweight

    full page →cagrilintide hydrochloride →source: globaldata
    ›Apr 28, 2026phase 1 initiation107d agoOvid Therapeutics Inc — OV-4071 (Phase I Trial Initiation)OV-4071

    Therapy area: Central Nervous System. Indication: Parkinson's Disease

    full page →OV-4071 →source: globaldata
    ›Apr 28, 2026phase 2 completion107d agoChangzhou Hengbang Pharmaceutical Co Ltd — HS-10374 (Phase II Trial Completion)HS-10374

    Therapy area: Musculoskeletal Disorders. Indication: Psoriatic Arthritis

    full page →HS-10374 →source: globaldata
    ›Apr 28, 2026phase 2 completion107d agoKS Hegde Medical Academy — fentanyl (Phase II Trial Completion)fentanyl ER

    Therapy area: Hormonal Disorders. Indication: Endocrine Gland Disorders

    full page →fentanyl ER →source: globaldata
    ›Apr 28, 2026phase 2 completion107d agoInonu University — albumin gel- and platelet- rich fibrin (Phase II Trial Completion)albumin gel- and platelet- rich fibrin

    Therapy area: Immunology, Mouth and Dental Disorders. Indication: Inflammation, Periodontal Disease, Periodontitis

    full page →albumin gel- and platelet- rich fibrin →source: globaldata
    ›Apr 28, 2026phase 2 completion107d agoUmraniye Research Hospital — bupivacaine (Phase II Trial Completion)bupivacaine

    Therapy area: Central Nervous System. Indication: Post-Operative Pain

    full page →bupivacaine →source: globaldata
    ›Apr 28, 2026phase 2 completion107d agoAnanta Institute of Medical Sciences and Research Centre — levobupivacaine (Phase II Trial Completion)levobupivacaine

    Therapy area: Central Nervous System, Gastrointestinal. Indication: Inguinal Hernia, Post-Operative Pain

    full page →levobupivacaine →source: globaldata
    ›Apr 28, 2026phase 2 completion107d agoGastroenterological Association of Thailand — metadoxine (Phase II Trial Completion)metadoxine

    Therapy area: Gastrointestinal. Indication: Metabolic and Alcohol-Associated Liver Disease (MetALD), Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD or NAFLD)

    full page →metadoxine →source: globaldata
    ›Apr 28, 2026phase 2 completion107d agoTianjin Medical University Cancer Institute and Hospital — AG [gemcitabine + nab-paclitaxel] (Phase II Trial Completion)AG [gemcitabine + nab-paclitaxel]

    Therapy area: Oncology. Indication: Pancreatic Cancer

    full page →AG [gemcitabine + nab-paclitaxel] →source: globaldata
    ›Apr 28, 2026phase 2 completion107d agoHackensack Meridian Health Inc — carboplatin (Phase II Trial Completion)Carboplatin Pfizer

    Therapy area: Oncology. Indication: Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma

    full page →Carboplatin Pfizer →source: globaldata
    ›Apr 28, 2026phase 2 completion107d agoTamilnadu Government Dental College and Hospital — metformin (Phase II Trial Completion)metformin

    Therapy area: Mouth and Dental Disorders. Indication: Unspecified Mouth and Dental Disorders

    full page →metformin →source: globaldata
    ›Apr 28, 2026phase 2 completion107d agoArdabil University of Medical Sciences — chorionic gonadotropin (Phase II Trial Completion)chorionic gonadotropin

    Therapy area: Women's Health. Indication: Female Infertility

    full page →chorionic gonadotropin →source: globaldata
    ›Apr 28, 2026phase 2 completion107d agoShanghai Pulmonary Hospital — undisclosed programmed cell death protein 1 inhibitor (Phase II Trial Completion)undisclosed programmed cell death protein 1 inhibitor

    Therapy area: Oncology. Indication: Non-Small Cell Lung Cancer

    full page →undisclosed programmed cell death protein 1 inhibitor →source: globaldata
    ›Apr 28, 2026phase 2 completion107d agoAl-Mustansiriya University — platelet rich fibrin (Phase II Trial Completion)platelet rich fibrin

    Therapy area: Mouth and Dental Disorders. Indication: Periodontitis

    full page →platelet rich fibrin →source: globaldata
    ›Apr 28, 2026phase 2 completion107d agoWest China Hospital of Stomatology — dexamethasone (Phase II Trial Completion)dexamethasone

    Therapy area: Mouth and Dental Disorders. Indication: Aphthous Ulcers (Canker Sores)

    full page →dexamethasone →source: globaldata
    ›Apr 28, 2026phase 2 completion107d agoUniversity of Sao Paulo General Hospital — iloprost (Phase II Trial Completion)iloprost

    Therapy area: Cardiovascular. Indication: Pulmonary Arterial Hypertension

    full page →iloprost →source: globaldata
    ← prev
    page 15 of 84
    next →
    $GSK50.09-1.59%
    $GSK50.09-1.59%
    $GSK50.09-1.59%
    $GSK50.09-1.59%
    $MRK132.84+1.86%
    $GSK50.09-1.59%
    $OVID2.6150+1.36%